Douglas Pharmaceuticals has officially opened a $50m R&D facility in west Auckland and unveiled new research into treatments for inflammatory bowel disease and the condition which causes cervical cancer.
The family-owned pharmaceutical firm is investing heavily in repurposing existing drugs to treat
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
